Sign in
Taking peopleNo phase

Broccoli sprout extract for memory and thinking in mild cognitive impairment

Tests broccoli sprout extract for thinking skills and safety in adults with mild cognitive impairment.

Key facts

Who runs it
Pusan National University Yangsan Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Broccoli Sprout Extract for Cognitive Function
Status
Recruiting
People taking part
100 people, planned
Started
16 Apr 2025
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Broccoli sprout extract (BSE)
  • Placebo Control
Record updated
13 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild memory or thinking problems but no dementia. Participants take broccoli sprout extract or a placebo for 12 weeks.

Age
55 to 85 years in the criteria (the registry age fields say 50 to 85 years).
Sex
Men and women can join.
Disease stage
Global Deterioration Scale (GDS) score of 2-3: memory complaints without test evidence (GDS 2), or mild memory problems shown on tests (GDS 3). No dementia.
Earlier treatment
No drugs or health functional foods that may affect thinking in the past month, such as antipsychotics, cognitive enhancers, tricyclic antidepressants or hormone replacement therapy. No other drug trial in the past month.

Main reasons for not taking part

  • Dementia, Parkinson's disease, stroke or other conditions linked to memory decline.
  • Serious stroke, heart disease or cancer in the past 6 months.
  • Uncontrolled blood pressure (≥160/100 mmHg) or, in people with diabetes, fasting blood sugar ≥160 mg/dL (8.9 mmol/L).
  • Kidney or liver problems (creatinine, AST or ALT ≥2 times the upper limit of normal), or uncontrolled thyroid disease.
  • Severe alcohol use disorder, severe stomach symptoms, allergy to the study product, or not able to read Korean.

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age: Adults aged 55-85 years (inclusive), both male and female
  • Global Deterioration Scale (GDS) score of 2-3:; GDS 2: Subjective memory impairment without objective evidence GDS 3: Mild objective memory impairment
  • Absence of dementia according to established diagnostic criteria
  • Ability to read Korean

Who cannot take part

  • Uncontrolled thyroid dysfunction: Currently receiving treatment for uncontrolled hypothyroidism or hyperthyroidism
  • Other clinical trial participation: Participation in other drug clinical trials within the past month or planned participation during the study period
  • Severe medical conditions within the past 6 months: History of severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage), cardiac disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignancy (Note: Participants with a history of cerebrovascular or cardiac disease who are clinically stable may be included at the investigator's discretion)
  • Cognitive impairment-associated diseases: Dementia, Parkinson's disease, cerebral infarction, or other conditions associated with cognitive decline Uncontrolled hypertension: Blood pressure ≥160/100 mmHg (measured after 10 minutes of rest)
  • Medications affecting cognitive function within the past month: Use of drugs (antipsychotics, anti-degenerative agents, cognitive enhancers, tricyclic antidepressants, hormone replacement therapy) or health functional foods that may influence cognitive function due to dementia or other cognitive abnormalities
  • Alcohol use disorder, severe
  • Food allergies: Known allergic reactions to study product components
  • Investigator discretion: Any other condition deemed inappropriate for study participation by the investigator
  • Poor glycemic control: Fasting blood glucose ≥160 mg/dL in diabetic patients
  • Renal impairment: Serum creatinine ≥2 times the upper limit of normal for the institution
  • Hepatic impairment: AST or ALT ≥2 times the upper limit of normal for the institution
  • Severe gastrointestinal symptoms: Complaints of severe heartburn, dyspepsia, or other gastrointestinal distress

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 50 and 85 years old?

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial aims to determine whether broccoli sprout extract improves cognitive function in adults with mild cognitive impairment and to assess its safety.

Read full original descriptionShow less

The main questions are:

* Does broccoli sprout extract improve cognitive function in participants? * What side effects occur when participants take broccoli sprout extract?

The 2 groups in the trial

  • Broccoli groupTreatment being tested

    This group takes broccoli sporout extract for 12 weeks.

    Treatment: Broccoli sprout extract (BSE)

  • Placebo groupPlacebo, for comparison

    This group takes placebo for 12 weeks.

    Treatment: Placebo Control

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A 12-week Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Broccoli Sprout Extract on Cognitive Function Improvement in Adults With Mild Cognitive Impairment
Plain-language title
Broccoli sprout extract for memory and thinking in mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07334366, who can take part
Record updated
13 January 2026